Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NMBR | P28336 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746741 | 0.82 | LMNA (0.61) | LMNASMN1; SMN2IDO1HTTNMBR | |
| SCHEMBL6561678 | 0.76 | LMNA (0.46) | LMNASMN1; SMN2IDO1HTTL3MBTL1 | |
| SCHEMBL6561749 | 0.74 | LMNA (0.44) | LMNASMN1; SMN2IDO1HTTL3MBTL1 | |
| SCHEMBL6563173 | 0.71 | HTT (0.48) | LMNASMN1; SMN2IDO1HTTL3MBTL1 | |
| SCHEMBL4667297 | 0.70 | LMNA (0.61) | LMNASMN1; SMN2IDO1HTTNMBR | |
| SCHEMBL6563145 | 0.70 | LMNA (0.46) | LMNASMN1; SMN2IDO1HTTNMBR | |
| Benzyl Phenethylcarbamate SCHEMBL4287199 | 0.69 | LMNA (0.73) | LMNASMN1; SMN2IDO1HTTL3MBTL1 | |
| SCHEMBL21848124 | 0.69 | LMNA (0.60) | LMNASMN1; SMN2IDO1HTTL3MBTL1 | |
| SCHEMBL535090 | 0.69 | LMNA (0.60) | LMNASMN1; SMN2IDO1HTTL3MBTL1 | |
| SCHEMBL29682187 | 0.69 | LMNA (0.60) | LMNASMN1; SMN2IDO1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | LMNA 4815/4885SMN1; SMN2 208/4885IDO1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.